| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f7ddc4774cf5f8a0bda44a780d73c53d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-605
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-50 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 |
| filingDate |
2014-01-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a763b4e835f40ab1b6b36d46eb2e93bc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_94e5d0dcca4dfe1203153bad85a98cb2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cb1b1a43664d47cbf5eda0b7619d3dfa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_62c72bd22b425207572474ad9dd22d60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c6582a1c726f4ed70db235e8ba3ad5dc |
| publicationDate |
2014-11-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
TW-201441253-A |
| titleOfInvention |
Insulin peptide derivative with N-terminal charge modification |
| abstract |
The present invention relates to an insulinotropic peptide derivative having a modified N-terminal charge and a pharmaceutical composition comprising the same. Specifically, the insulinotropic peptide derivative is characterized in that the N-terminal positive charge of the insulinotropic peptide is modified to a neutral or negative charge at a neutral pH. The insulinotropic peptide derivative according to the present invention is rapidly dissociated from the GLP-1 receptor by the above-described modification of the N-terminal charge in comparison to the natural insulinotropic peptide to maintain blood stability and exhibit enhanced insulinotropic ability and Blood glucose lowers activity. Therefore, the insulinotropic peptide derivative is very useful for the treatment of type 2 diabetes. |
| priorityDate |
2013-01-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |